The Series C round financing will be used to fund a phase 3 trial of its lead drug, SER-109, intended to prevent the recurrence of Clostridium difficile infection. The drug is considered a biologic by the U.S. Food and Drug Administration. Early stage trial results showed that the use of the drug resulted in 29 out of 30 patients remaining infection-free for two months, according to the report.
More articles on gastroenterology:
ASGE, ACG update GI procedure quality indicators: 4 things to know
FDA approves Aer-O-Scope Colonoscope System
4 gastroenterologists on the move
